Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Catalent to produce Oxford vaccine for AstraZeneca

by Rick Mullin
August 28, 2020 | A version of this story appeared in Volume 98, Issue 33

 

AstraZeneca has contracted with Catalent to produce its adenovirus vector–based COVID-19 vaccine candidate, AZD1222, at Catalent’s gene therapy facility in Harmans, Maryland. Catalent is preparing to operate multiple lines in parallel to produce the vaccine by the start of the fourth quarter. AstraZeneca already has production deals with firms including Emergent BioSolutions and Serum Institute of India. AZD1222 was invented at the University of Oxford and licensed by AstraZeneca. It is currently in clinical trials.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.